Clinical Trials · NCT00044694
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 156
- Start date
- Aug 2002
- Locations
- 33 sites, United States
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28